| GTO ID | GTC0696 |
| Trial ID |
2021-002192-19
|
| Disease |
Familial Hypercholesterolemia
|
| Altered gene | APOC3 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Olezarsen|ISIS 678354|IONIS-APOCIII-LRx|AKCEA-APOCIII-LRx |
| Phase | Phase3 |
| Recruitment status | Ongoing |
| Title | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia |
| Year | 2022 |
| Country | Australia|Bulgaria|Canada|Czechia|Denmark|Finland|France|Germany|Hungary|Israel|Italy|Netherlands|New Zealand|Norway|Poland|Portugal|Slovakia|South Africa|Spain|Sweden|Turkey|United Kingdom|United States |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | NCT05079919|ISIS 678354-CS5 |